NCT02603081View on ClinicalTrials.gov

Study to Evaluate SPI-1005 in Adults With Meniere's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Meniere's Disease
Interventions
DRUG

SPI-1005

Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.

Trial Locations (5)

10028

New York Otology, New York

29425

MUSC, Charleston

90057

House Clinic, Los Angeles

98103

Sound Pharmaceuticals, Inc., Seattle

98104

Northwest Ear, Seattle

All Listed Sponsors
lead

Sound Pharmaceuticals, Incorporated

INDUSTRY

NCT02603081 - Study to Evaluate SPI-1005 in Adults With Meniere's Disease | Biotech Hunter | Biotech Hunter